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ABSTRACT 
Objective: The fibroblast growth factor (FGF) family of signaling molecules has been 
associated with chemoresistance and poor prognosis in a number of cancer types, including 
lung, breast, ovarian, prostate, and head and neck carcinomas. Given the identification of 
activating mutations in the fibroblast growth factor receptor 2 (FGFR2) receptor tyrosine 
kinase in a subset of endometrial tumors, agents with activity against FGFRs are currently 
being tested in clinical trials for recurrent and progressive endometrial cancer. Here we 
evaluated the effect of FGFR inhibition on the in vitro efficacy of chemotherapy in 
endometrial cancer cell lines. 
Methods: Human endometrial cancer cell lines with wildtype or activating FGFR2 mutations 
were utilized to determine any synergism with concurrent use of the pan-FGFR inhibitor, 
PD173074, and the chemotherapeutics, doxorubicin and paclitaxel, on cell proliferation and 
apoptosis. 
Results: FGFR2 mutation status did not alter sensitivity to either chemotherapeutic agent 
alone. The combination of PD173074 with paclitaxel or doxorubicin showed synergistic 
activity in the three FGFR2 mutant cell lines evaluated. In addition, though non-mutant cell 
lines were resistant to FGFR inhibition alone, the addition of PD173074 potentiated the 
cytostatic effect of paclitaxel and doxorubicin in a subset of FGFR2-wildtype endometrial 
cancer cell lines. 
Conclusions: Together these data suggest a potential therapeutic benefit to combining an 
FGFR inhibitor with standard chemotherapeutic agents in endometrial cancer therapy 
particularly in patients with FGFR2 mutation positive tumors.  
Key words: endometrial cancer, chemotherapy, synergy, FGFR, PD173074 
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INTRODUCTION 
Uterine cancer is the seventh most commonly diagnosed malignancy in women 
globally, with an estimated 46,470 cases and 8,120 deaths in the United States alone in 2011.1 
Endometrial cancer comprises approximately 90% of uterine cancer burden and, although it 
is typically diagnosed at an early stage with a favorable prognosis (5-year survival rate 
greater than 80%), prognosis is poor for patients with advanced or recurrent tumors.2 
Chemotherapy is the standard treatment for patients with locally advanced or recurrent 
endometrial cancer. The most active agents for chemotherapy-naive patients are platinum 
agents, taxanes, and anthracyclines, producing single agent response rates of 20-30% and 
increased response rates (33-57%) when given in combination.3 Unfortunately, the elderly 
status and multiple co-morbidities of many patients with recurrent or advanced disease limits 
the use and dose of these chemotherapeutic agents because of toxicity.3 In such cases, 
hormonal therapy should be considered owing to the minimal side effects associated with this 
treatment modality.3 
The identification of effective targeted agents is a clinically unmet need in 
endometrial cancer. Once validated in preclinical studies, these agents will be evaluated 
alone, or often in combination with chemotherapies currently offered as standard of care. The 
tyrosine kinase receptor fibroblast growth factor receptor 2 (FGFR2) is an emerging 
therapeutic target in endometrial cancer. Activating mutations in FGFR2 occur in 
approximately 10% of endometrioid endometrial tumors,4-6 and FGFR2 mutant endometrial 
cancer cells are selectively sensitive to FGFR inhibition, undergoing cell cycle arrest and cell 
death in response to the pan-FGFR inhibitor PD173074.4, 7 Currently, several kinase 
inhibitors with activity against multiple kinases including FGFRs are being evaluated in 
endometrial patients with advanced stage or recurrent endometrial cancer (Brivinib, 
NCT00888173; E7080, NCT01111461, BIBF1120, NCT01225887; Dovitinib,  
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NCT01379534, ClinicalTrials.gov). In addition, more specific anti-FGFR agents, including 
AZD4547 (NCT00979134) and BGJ398 (NCT01004224) are currently being evaluated in 
other tumor types with confirmed FGFR mutations or amplifications. 
Several members of the FGF/FGFR family of signaling molecules have been 
implicated in chemoresistance. FGF2 has been the most well studied, with reports that 
overexpression or incubation with FGF2 can protect against chemotherapy-induced cell death 
in a number of different cell types. For example, incubation with FGF2 has been shown to 
block etoposide-induced apoptosis in lung cancer cells,8 to protect against paclitaxel, 
doxorubicin and 5-FU in PC-3 prostate cells,9 and to be cytoprotective in endothelial cells 
following exposure to doxorubicin, cisplatin, paclitaxel or vinblastine.10 In some cell types 
insights into the mechanism by which FGF-2 provides chemoresistance has been provided, 
such as upregulation of anti-apoptotic molecules including Bcl-2, Bcl-XL8 and survivin.10 
FGF1 has also been associated with chemoresistance by augmenting the effect of FGF2,9 and 
FGF7 has been shown to have marked cytoprotective effects in breast cancer cells in reponse 
to chemotherapy.11, 12 In keeping with these findings, inhibition of FGFR activation has been 
shown to restore chemosensitivity in various cancer types. In addition, amplification of 
FGFR4 has been associated with resistance of breast cancer cells to doxorubicin, and 
inhibition with a FGFR4 blocking antibody was shown to reduce this chemoresistance.13 
Knockdown of FGFR1 and FGFR2 in ovarian cancer cell lines has also recently been shown 
to enhance cisplatin sensitivity.14  
The role of FGF signaling in the chemotherapeutic response in endometrial cancer has 
not been studied. Therefore we sought to determine whether inhibition of FGFR signaling 
increases the effect of common chemotherapeutic agents in endometrial cancer cell lines with 
and without FGFR2 mutations. Here we report that the pan-FGFR inhibitor PD173074 
synergizes with paclitaxel and doxorubicin in endometrial cell lines carrying mutationally 
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activated FGFR2 and, in addition, potentiates the effect of paclitaxel and doxorubicin in a 
subset of endometrial cancer cell lines with wildtype FGFR2.  
 
METHODS 
Cell Lines and Reagents 
The MFE296 cell line was purchased from the European Collection of Cell Cultures 
(Salisbury). AN3CA, HEC1A, Ishikawa, and KLE cells were provided by Dr. Paul 
Goodfellow (Washington University, St. Louis, MO). AN3CA, MFE296, HEC1A, Ishikawa, 
and KLE cells were cultured as previously described.7 MFE280 cells were obtained from the 
German Tissue Repository DSMZ (Braunschweig, Germany) and cultured as recommended 
in 40% RPMI 1640, 40% MEM with Earle's salts, 20% FBS, 2 mM L-glutamine, and insulin-
transferrin-sodium selenite. Paclitaxel, doxorubicin, and PD173074 were purchased from 
Sigma Aldrich (St. Louis, MO). Paclitaxel was resuspended in DMSO to a stock solution of 1 
mM and doxorubicin was resuspended in water to a stock solution of 2 mg/mL (3.45mM). 
FGF1, FGF7, and FGF10 were purchased from R&D Systems (Minneapolis, MN).  
In vitro Proliferation Assays 
The single agent growth inhibition effect of doxorubicin and paclitaxel was measured 
using the sulforhodamine B (SRB) assay. Cells were plated at a density of 3,000 cells/well in 
96 well plates and chemotherapeutic agents added to triplicate wells using half-log serial 
dilutions, from 1000 nM to 0.1 nM for paclitaxel and 10 µM to 1 nM for doxorubicin. The 
SRB assay was performed 72 hours after drug addition as previously described.7 Data were 
analyzed and IC50 values generated by nonlinear regression analysis with variable slope 
using Prism software (GraphPad software, San Diego, CA). For chemoprotective studies, 1 
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nM FGF1, FGF7, or FGF10 and 5 µg/ml heparin were added to triplicate wells 1 hour prior 
to the addition of doxorubicin (10 µM to 1 nM) or paclitaxel (30 nM to 0.01 nM). For 
combination studies of PD173074 with paclitaxel or doxorubicin, the FGFR inhibitor, 
PD173074, was added 1 hour prior to the addition of the chemotherapeutic agents. 
Median-effect analysis 
Synergy between PD173074 and paclitaxel or doxorubicin was evaluated using 
median effect analysis as described by Chou and Talalay.15 Drugs were added at non-fixed 
ratios, such that fixed concentrations of PD173074 (10 nM to 300 nM) were added with 
increasing concentrations of paclitaxel (0.1 nM to 10 nM) or doxorubicin (3 nM to 1000 nM). 
The SRB assay was performed 72 hours after drug addition. Median effect analysis was 
performed using CalcuSyn software (Biosoft, Cambridge, UK). In this analysis, combination 
index (CI) < 1 indicates synergy, CI = 1 indicates zero interaction (strictly additive effects) 
and CI > 1 indicates antagonism. 
Bliss additivity analysis 
The Bliss additivity model was used to determine whether the effect of combining 
PD173074 with paclitaxel or doxorubicin was more than additive in cell lines that were not 
sensitive to PD173074 alone (i.e. FGFR2 wildtype cell lines: HEC1A, Ishikawa, KLE). In 
this model, the predicted additive effect was calculated based on the individual effects of 
each agent, such that the predicted Bliss additive effect = Effect drug A + Effect drug B – 
(Effect drug A x Effect drug B). The actual experimental effects were then graphed relative 
to the predicted Bliss additive effects. An actual experimental value less than the predicted 
Bliss additivity effect indicates potentiation. Bliss values were calculated to represent the 
increase in effect with drug combination compared to strictly additive interactions,16 such that 
the Bliss value = the experimental effect – the predicted bliss effect. A Bliss value equal to 
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zero indicates a solely additive interaction, a Bliss value greater than zero indicates 
potentiation, and less than zero indicates antagonism. Bliss values across concentration 
combinations were calculated to produce an average bliss value for each drug combination. 
Cell Death Analysis by Annexin Staining 
Annexin V-FITC staining was used to measure phosphatidylserine exposure on cells 
undergoing apoptosis according to the manufacturer’s instructions (BioVision, Inc. Mountain 
View, CA). 2.5x105 cells were plated per well in a 6 well plate. Cells were treated with 
0.01% DMSO, 3 nM (AN3CA, MFE296, HEC1A, Ishikawa) or 30 nM (MFE280, KLE) 
paclitaxel, 10 nM (Ishikawa), 100 nM (AN3CA, MFE296, HEC1A) or 300 nM (MFE280, 
KLE) doxorubicin or 300 nM PD173074 with or without paclitaxel/doxorubicin 24 hours 
after plating. We chose concentrations of chemotherapy close to the individual cell line’s 
IC50, as measured previously by SRB assay, to ensure there was enough scope for 
observation of any synergistic effect of their combination with the FGFR inhibitor 
PD173074. After 72 hours, floating and attached cells were collected and resuspended in 
Annexin binding buffer (10mM Hepes (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2). Following 
the addition of 500 ng/mL annexinV-FITC and 1 µg/mL propidium iodide (Sigma-Aldrich, 
St. Louis, MO), cells were analysed for annexin positive cells using a CyAn ADP flow 
cytometer and Summit software, version 4.3 (Dako Cytomation, Carpinteria, CA). 
 
RESULTS 
Sensitivity to chemotherapeutic agents 
The efficacy of paclitaxel and doxorubicin was evaluated in a panel of endometrial 
cancer cell lines consisting of three cell lines which possess activating mutations in FGFR2 
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(AN3CA, MFE280 and MFE296) and three which are wildtype for FGFR2 (HEC1A, 
Ishikawa and KLE) using the SRB assay. As shown in Figure 1A-C, FGFR2 mutant cell lines 
did not display differential sensitivity to either chemotherapeutic agent tested when compared 
to FGFR2 wildtype cell lines.  
FGF ligand expression has been associated with chemoresistance in various cancer 
types.9, 12, 17, 18 To determine whether FGF ligand stimulation would promote drug resistance 
in endometrial cancer cell lines, we pretreated AN3CA (FGFR2 mutant) and Ishikawa 
(FGFR2 wildtype) cells with FGF1 (universal FGF ligand recognized by all FGFRs), and 
FGF7 and FGF10 (FGFR2b specific ligands) for 1 hour prior to chemotherapy addition after 
which SRB assays were again performed. Pretreatment with FGF1, FGF7, or FGF10 did not 
alter sensitivity to paclitaxel or doxorubicin in either cell line (Fig. 2). Similar results were 
observed in MFE280, MFE296, KLE, and HEC1A cell lines (data not shown). A longer 
pretreatment of 4 hours with 100 ng/mL FGF1 was also tested in AN3CA and MFE280 cells, 
but there was no effect on paclitaxel or doxorubicin sensitivity in either cell line (data not 
shown). 
Synergism of FGFR inhibition with chemotherapeutic agents in FGFR2 mutant endometrial 
cancer cells. 
The efficacy of molecularly targeted agents can often be enhanced by co-
administration with cytotoxic anticancer agents. Indeed, SU6668, a tyrosine kinase inhibitor 
of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor 
receptor (PDGFR)-β and FGFR1 exhibited synergistic activity with paclitaxel in ovarian 
carcinoma xenograft models.19 Therefore, we sought to determine whether specific FGFR 
inhibition enhanced the activity of paclitaxel or doxorubicin in endometrial cancer cells. 
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Synergy of the pan-FGFR inhibitor PD173074 with paclitaxel or doxorubicin was evaluated 
using the non-fixed ratio median effect analysis method of Chou and Talalay.15 
We first investigated the efficacy of combining PD173074 with chemotherapy on the 
proliferation of endometrial cancer cell lines by an SRB assay. The concentration response 
curves for single agent PD173074 as well as PD173074 combined with paclitaxel or 
doxorubicin in AN3CA, MFE280 and MFE296 cells are presented in Supplemental Figures 1 
and 2 respectively. This data was used to calculate the Combination Index values presented in 
Figure 3. As displayed in Figure 3A-F, PD173074 exhibited synergistic anti-proliferative 
effects (Combination Index < 0.8) with paclitaxel and doxorubicin in all three FGFR2 mutant 
endometrial cancer cell lines tested (AN3CA, MFE280, MFE296). Both AN3CA and 
MFE280 cell lines demonstrated obvious synergy with PD173074 and paclitaxel or 
doxorubicin co-administration across the entire range of drug concentrations evaluated (Fig. 
3A-D). The MFE296 cell line showed synergistic interactions for all but the lowest 
concetrations of paclitaxel and PD173074 drug concentrations tested (Fig. 3E).  
 
FGFR inhibition potentiated the cytostatic activity of chemotherapy in a subset of FGFR2 
wildtype endometrial cancer cells 
As outlined previously, the addition of exogenous FGF ligand did not alter sensitivity 
to doxorubicin or paclitaxel in the panel of cell lines tested (Fig. 2). However, FGFs, 
including FGF7, are known to be expressed by several endometrial cancer cell lines,20-22 thus 
possibly masking any effect of exogenously added ligand. Therefore, we evaluated whether 
FGFR inhibition would sensitize wildtype FGFR2 endometrial cancer cell lines to 
chemotherapeutic agents.  
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One of the prerequisites for calculation of a combination index is that each drug alone 
must have a dose-effect relationship, such that potency (IC50) can be calculated. As 
endometrial cancer cell lines with wildtype FGFR2 are not sensitive to PD173074, the 
alternative Bliss additivity model was used to evaluate potentiation of doxorubicin’s or 
paclitaxel’s effect on proliferation with PD173074 treatment in the endometrial cancer cell 
lines with wildtype FGFR2. 
Treatment with a low concentration (10 nM) of PD173074 enhanced the response of 
FGFR2 wildtype KLE endometrial cells to doxorubicin treatment (Fig. 4A). This potentiation 
of effect was further enhanced with increasing concentrations of PD173074 (Fig. 4A). 
PD173074 treatment also potentiated the cytostatic effect of paclitaxel in KLE and Ishikawa 
cells, but had no effect on the response of HEC1A cells to paclitaxel (Fig. 4B). Treatment 
with the FGFR inhibitor also potentiated the effect of doxorubicin in KLE cells (Fig. 4B). 
However, PD173074 did not affect the doxorubicin response in HEC1A cells and even 
showed antagonistic interactions with doxorubicin in Ishikawa cells (Fig. 4B).  
 
Effect of combined FGFR inhibition and chemotherapy on cell death in endometrial cancer 
cells 
We have previously demonstrated that PD173074 induces cell death in AN3CA and 
MFE280, but not MFE296 cells.7 Doxorubicin and paclitaxel have also been shown to induce 
cell death in endometrial cancer cells.23, 24 Therefore, we evaluated whether the synergy 
observed in previous proliferation assays with the combination of these agents was the result 
of enhanced cytotoxicity. AN3CA, MFE280, and MFE296 cells were treated with PD173074, 
paclitaxel, or the combination and cell death measured 72 hours later by Annexin staining. As 
shown in Figure 5A, single agent treatment of both PD173074 and paclitaxel resulted in 
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Annexin staining and hence cell death, with the exception of PD173074 therapy in MFE296 
cells. Co-administration of PD173074 and paclitaxel revealed an additive cytotoxic response 
in both AN3CA and MFE280 cells. In contrast, PD173074 did not enhance the cell death 
effect of paclitaxel in MFE296 cells (Fig. 5A). Thus, PD173074 and paclitaxel do not 
synergize to induce cell death, but do exhibit additive effects in cells where PD173074 alone 
induces cell death. We similarly compared the cytotoxic efficacy of PD173074 and 
doxorubicin co-administration with either drug used alone. PD173074 did not increase 
doxorubicin-induced cell death in AN3CA, MFE280, or MFE296 cells (Fig. 5A), despite 
demonstrating synergistic activity at these concentrations in the proliferation studies outlined 
above. Furthermore, PD173074 decreased the cytotoxic effect of doxorubicin in MFE280 and 
MFE296 cells (Fig. 5A).  
We also evaluated the cytotoxic efficacy of combined FGFR inhibition and 
chemotherapy in endometrial cell lines with wildtype FGFR2. Similar to our findings in 
FGFR2-mutant cell lines, PD173074 did not potentiate the induction of cell death by either 
doxorubicin or paclitaxel in FGFR2-wildtype KLE, Ishikawa, or HEC1A cells (Fig. 5B). 
PD173074 decreased the cytotoxic activity of doxorubicin in HEC1A and Ishikawa cells, 
albeit PD173074 treatment alone also decreased annexin positivity to a similar extent when 
compared to DMSO controls (Fig. 5B). 
 
DISCUSSION 
FGFR2 is an emerging therapeutic target in endometrial cancer following the 
identification of activating mutations in FGFR2 in a subset of endometrial tumors and the 
demonstration that FGFR2-mutant endometrial cancer cells are selectively sensitive to FGFR 
inhibition suggestive of pathway addiction.4, 5, 7 As such, clinical trials are currently 
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underway evaluating agents with anti-FGFR activity in endometrial cancer. Most of these 
trials are evaluating anti-FGFR agents in monotherapy, although the most effective approach 
to incorporate these agents into existing therapeutic regimens remains to be formally 
determined. Of note, several targeted biological agents, including trastuzumab, cetuximab, 
and bevacizumab, have shown enhanced efficacy in a clinical setting when combined with 
conventional chemotherapies.25-27 Other receptor tyrosine kinase inhibitors, such as the FLT3 
inhibitor midostaurin, are also being trialed in combination with chemotherapy, after showing 
initial efficacy as a single agent in the clinic28 and synergistic activity with chemotherapeutics 
in vitro.29 Here we report increased in vitro efficacy of doxorubicin and paclitaxel when 
combined with the pan-FGFR inhibitor PD173074 in endometrial cancer cell lines with or 
without FGFR2 mutations.  
Previous studies have demonstrated enhanced anti-tumor activity upon combination 
of an FGFR inhibitor and cytotoxic chemotherapeutics in a variety of cancer types.30-33 In the 
current study, FGFR inhibition exhibited synergistic activity on cell proliferation when 
combined with paclitaxel and doxorubicin in AN3CA, MFE280 and MFE296 endometrial 
cancer cell lines in vitro. These cell lines express the most common activating FGFR2 
mutations observed in endometrial tumors, with AN3CA and MFE296 cells expressing the 
N550K kinase domain mutation and MFE280 cells expressing the ligand-dependent S252W 
mutation. We have previously shown that AN3CA and MFE280 cells undergo G1 cell cycle 
arrest and cell death following PD173074 treatment whereas MFE296 cells exhibit a solely 
cytostatic response to FGFR inhibition.7 Here we demonstrate that in AN3CA and MFE280 
cells, PD173074 exhibited synergistic anti-proliferative activity with paclitaxel and 
doxorubicin across the range of concentrations tested. Similarly, for MFE296 cells, 
PD173074 treatment also displayed synergism with paclitaxel and doxorubicin, albeit not at 
the lowest concentrations tested in these cells. 
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In addition to mutant FGFR2 endometrial cancer cell lines, FGFR inhibition with 
PD173074 also potentiated the cytostatic effect of paclitaxel and doxorubicin in a subset of 
cell lines with wildtype FGFR2. Caution, however, must be exercised in advocating such a 
combination for EC patients with wildtype FGFR2 owing to our findings that FGFR 
inhibition may also antagonize the anticancer activity of chemotherapy, such as that observed 
for Ishikawa cells treated with PD173074 and doxorubicin. 
The observed synergistic cytostatic activity of combined FGFR inhibition and 
chemotherapy appears to be largely independent of an enhanced cytotoxic effect. Our 
annexin data demonstrate that although PD173074 can enhance the cell death response of 
paclitaxel in AN3CA and MFE280 cells, this increased response is only additive and not 
synergistic. Furthermore, combined PD173074 and chemotherapy also demonstrate synergy 
on cell proliferation in MFE296 cells despite FGFR inhibition having no cytotoxic action 
when given alone in this cell line. 
PD173074 co-treatment also failed to increase doxorubicin-induced cell death in any 
of the cell lines tested. Moreover, in MFE280 and MFE296 cells PD173074 decreased the 
cell death response to doxorubicin. Given that PD173074 induces G1 cell cycle arrest in 
AN3CA, MFE280, and MFE296 cells7 and doxorubicin works to arrest cells in G2/M34, we 
hypothesize that the induction of G1 arrest by FGFR inhibition reduces the proportion of 
cells in G2/M and thus the number of cells that would be sensitive to the cytotoxic effects of 
doxorubicin. This proposed effect may also explain the solely additive cytotoxic effects 
observed with combined paclitaxel and PD173074 in MFE280 and AN3CA cells. Parallels 
can perhaps be drawn from experience with EGFR inhibition by erlotinib or gefitinib and 
chemotherapy in non-small cell lung cancer (NSCLC). Despite preclinical studies 
demonstrating additive or synergistic effects when combining EGFR inhibitors with 
cytotoxic agents, four randomized phase III clinical trials evaluating concurrent 
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administration of EGFR TKI and chemotherapy have demonstrated no survival benefit of this 
combination over chemotherapy alone in NSCLC.35-38 To explain this phenomenon a 
pharmacodynamic separation model has been proposed, where EGFR inhibitors primarily 
cause cell cycle arrest and accumulation of cells in G1, like FGFR inhibitors, and thus 
possibly interfere with mitotic-specific cytotoxicity of chemotherapy.39 As such, FGFR 
inhibitors may also be best given intermittently or sequentially with chemotherapy in the 
context of endometrial cancer to overcome their divergent effects on cell cycle arrest. 
Treatment of both FGFR2-mutant and FGFR2-wildtype endometrial cancer lines with 
the FGF ligands 1, 7 and 10 did not alter the chemosensitivity to paclitaxel or doxorubicin in 
any of the six cell lines studied. This is not wholly unsurprising given the evidence that a 
chemoprotectant effect for FGF ligands may be specific to FGF2.9 For example, Song et al.9 
show FGF2 drives chemoresistance while FGF1 simply enhances the effect of FGF2. We 
chose these ligands, however, based on FGF7 and FGF10 being specific to FGFR2b, the 
FGFR2 isoform exclusively present in endometrial cells owing to their epithelial lineage, and 
the demonstrated ability of FGF7 to protect MCF-7 breast cancer cells from the cytostatic 
and cytotoxic effects of chemotherapy.11, 12 It should be noted that, although FGF1 is capable 
of binding all FGFRs, this data does not preclude a role for FGF2 and chemoprotection in 
endometrial cancer. 
The chemoprotective effects of growth factor signaling in endometrial cancer are 
generally thought to be due to pro-survival signaling mediated by activation of the AKT 
pathway.23, 40 We have previously shown, however, that FGFR2 mutations occur in the 
presence of PTEN abrogation in endometrial cancer7, suggesting that FGFRs do not 
predominantly signal through the PI3K-AKT pathway in endometrial epithelial cells. 
Moreover, we have demonstrated that inhibition of FGFRs with PD173074 induces cell death 
despite constitutive activation of AKT.7 Thus, for FGFR2 mutant cell lines, the synergistic 
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activity of PD173074 with paclitaxel and doxorubicin appears to be independent of the 
PI3K/AKT pathway. In the FGFR2-wildtype cell lines, the potentiation observed with 
PD173074 was also not associated with the activation status of the PI3K pathway.  
Our in vitro data presented here demonstrate that the pan-FGFR inhibitor, PD173074, 
directly potentiates the anti-tumor effects of doxorubicin and paclitaxel in endometrial cancer 
cells and particularly in those with mutant FGFR2. Together these data suggest a therapeutic 
benefit to combining an FGFR inhibitor with standard chemotherapeutic agents, and, 
importantly, this may extend to patients whose tumors possess wildtype FGFR2. As such, 
evaluation of clinically relevant FGFR inhibitors in combination with conventional 
chemotherapy within an in vivo setting is warranted. 
16 
 
REFERENCES 
1. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating 
socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61: 
212-236. 
2. Saso S, Chatterjee J, Georgiou E et al. Endometrial cancer. BMJ. 2011;343: d3954. 
3. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer 
Control. 2009;16: 38-45. 
4. Dutt A, Salvesen HB, Chen TH et al. Drug-sensitive FGFR2 mutations in endometrial 
carcinoma. Proc Natl Acad Sci U S A. 2008;105: 8713-8717. 
5. Pollock PM, Gartside MG, Dejeza LC et al. Frequent activating FGFR2 mutations in 
endometrial carcinomas parallel germline mutations associated with craniosynostosis and 
skeletal dysplasia syndromes. Oncogene. 2007;26: 7158-7162. 
6. Byron SA, Gartside M, Powell MA et al. FGFR2 point mutations in 466 endometrioid 
endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and 
clinicopathological features. PLoS One. 2012;7: e30801. 
7. Byron SA, Gartside MG, Wellens CL et al. Inhibition of activated fibroblast growth 
factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. 
Cancer Res. 2008;68: 6902-6907. 
8. Pardo OE, Arcaro A, Salerno G et al. Fibroblast growth factor-2 induces translational 
regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to 
etoposide-induced apoptosis. J Biol Chem. 2002;277: 12040-12046. 
9. Song S, Wientjes MG, Gan Y et al. Fibroblast growth factors: an epigenetic 
mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 
2000;97: 8658-8663. 
17 
 
10. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial 
cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99: 4349-4354. 
11. Rotolo S, Ceccarelli S, Romano F et al. Silencing of keratinocyte growth factor 
receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS One. 
2008;3: e2528. 
12. Tamaru N, Hishikawa Y, Ejima K et al. Estrogen receptor-associated expression of 
keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast 
cancer. Lab Invest. 2004;84: 1460-1471. 
13. Roidl A, Berger HJ, Kumar S et al. Resistance to chemotherapy is associated with 
fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009;15: 2058-2066. 
14. Cole C, Lau S, Backen A et al. Inhibition of FGFR2 and FGFR1 increases cisplatin 
sensitivity in ovarian cancer. Cancer Biol Ther. 2010;10: 495-504. 
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined 
effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22: 27-55. 
16. Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal 
growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast 
tumors. Mol Cancer Ther. 2006;5: 2676-2684. 
17. Miyake H, Hara I, Gohji K et al. Expression of basic fibroblast growth factor is 
associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 
1998;123: 121-126. 
18. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates 
with resistance to paclitaxel in human patient tumors. Pharm Res. 2006;23: 1324-1331. 
19. Garofalo A, Naumova E, Manenti L et al. The combination of the tyrosine kinase 
receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in 
ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res. 2003;9: 3476-3485. 
18 
 
20. Giavazzi R, Sennino B, Coltrini D et al. Distinct Role of Fibroblast Growth Factor-2 
and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. Am J Pathol. 
2003;162: 1913-1926. 
21. Sales KJ, Boddy SC, Williams AR et al. F-prostanoid receptor regulation of fibroblast 
growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology. 2007;148: 
3635-3644. 
22. Taniguchi F. Activation of Mitogen-Activated Protein Kinase Pathway by 
Keratinocyte Growth Factor or Fibroblast Growth Factor-10 Promotes Cell Proliferation in 
Human Endometrial Carcinoma Cells. J Clin Endocrinol Metab. 2003;88: 773-780. 
23. Gagnon V, Van Themsche C, Turner S et al. Akt and XIAP regulate the sensitivity of 
human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008;13: 259-271. 
24. Kim KK, Kawar NM, Singh RK et al. Tetrathiomolybdate induces doxorubicin 
sensitivity in resistant tumor cell lines. Gynecol Oncol. 2011;122: 183-189. 
25. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with 
advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. 
Lancet. 2009;373: 1525-1531. 
26. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for 
operable HER2-positive breast cancer. N Engl J Med. 2005;353: 1673-1684. 
27. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab 
for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550. 
28. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and 
an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, 
PKC412. Blood. 2005;105: 54-60. 
19 
 
29. Mollgard L, Deneberg S, Nahi H et al. The FLT3 inhibitor PKC412 in combination 
with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemother Pharmacol. 
2008;62: 439-448. 
30. Fischer H, Taylor N, Allerstorfer S et al. Fibroblast growth factor receptor-mediated 
signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic 
implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer 
Ther. 2008;7: 3408-3419. 
 
For the complete list of references, please contact pamela.pollock@qut.edu.au. 
 
 
 
20 
 
FIGURE LEGENDS 
Figure 1. In vitro sensitivity of endometrial cancer cell lines to paclitaxel and doxorubicin. 
Single agent dose response curves were generated for paclitaxel (A) and doxorubicin (B) in 
six endometrial cancer cell lines using the SRB assay (representative curves shown). C, The 
average IC50 value from three independent experiments is also presented. 
Figure 2. FGF ligand stimulation does not alter endometrial cancer cell line sensitivity to 
doxorubicin or paclitaxel. AN3CA (A) and Ishikawa (B) cells were stimulated with 1 nM 
FGF1, FGF7, or FGF10 and 5 µg/ml heparin in full growth media 1 hour prior to 
chemotherapy treatment. The SRB assay was performed 72 hours after paclitaxel or 
doxorubicin treatment. Values were normalized to stimulation with the respective FGF ligand 
alone and dose response curves generated. Data were graphed as follows: chemotherapy 
alone (square), chemotherapy + FGF1 (circle), chemotherapy + FGF7 (down triangle), 
chemotherapy + FGF10 (up triangle). 
Figure 3. PD173074 exhibits synergistic cytostatic activity with paclitaxel and doxorubicin 
in endometrial cancer cell lines with FGFR2 mutations. PD173074 and either paclitaxel or 
doxorubicin were added in combination at non-fixed ratios (increasing concentrations of 
paclitaxel (A, C, E) or doxorubicin (B, D, F) in the presence of a constant concentration of 
PD173074) to AN3CA (A, B), MFE280 (C, D) and MFE296 (E, F) cells. Seventy-two hours 
later, the SRB assay was performed. Synergy was evaluated using CalcuSyn software, where 
synergy is defined as a combination index of <1. Different PD173074 concentrations were 
graphed as follows: 10 nM (blue circle), 30 nM (red square), 100 nM (green up triangle), 300 
nM (purple down triangle). 
Figure 4. PD173074 potentiates the cytostatic effect of paclitaxel and doxorubicin in a subset 
of endometrial cancer cell lines with wildtype FGFR2. A, KLE cells were pretreated with 
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PD173074 (10 nM, 30 nM, 100 nM or 300 nM) for one hour and then treated with increasing 
concentrations of doxorubicin and 72 hours later, cell number was measured with the SRB 
assay. The predicted Bliss additivity response was calculated as described in Materials and 
Methods and graphed compared to actual experiment values using Prism software. 
Doxorubicin treatment alone is represented by the red solid line with closed squares. 
Doxorubicin plus PD173074 (“Experimental” group) is indicated by the blue closed circles 
and solid line. The predicted Bliss response (representing the response if PD173074 and 
doxorubicin exhibit solely additive interactions) is depicted by the blue dashed line with open 
circles. An experimental value less than the predicted Bliss value indicates potentiation of 
effect. As shown, the predicted Bliss response with PD173074 almost represents the same 
curve as doxorubicin treatment alone, as endometrial cancer cells with wildtype FGFR2, like 
KLE, are not sensitive to PD173074. B, Bliss value analysis of PD173074 and doxorubicin or 
paclitaxel in KLE, Ishikawa, and HEC1A cells. Bliss additivity data were analyzed as 
described in Materials and Methods to produce a Bliss score representing the average 
increase in inhibition observed across concentrations when PD173074 was combined with 
paclitaxel or doxorubicin compared to that expected for a strictly additive interaction. A Bliss 
value equal to zero indicates a directly additive interaction. A Bliss value greater than zero 
denotes potentiation of effect with combination treatment, while a Bliss value less than zero 
indicates antagonism when the two agents are combined. 
Figure 5. Cytotoxic action of PD173074 with chemotherapy in endometrial cancer cells with 
mutant or wildtype FGFR2. PD173074 (300 nM) and either paclitaxel or doxorubicin were 
added alone or in combination to (A) FGFR2-mutant AN3CA, MFE280 and MFE296 cells 
and (B) FGFR2-wildtype HEC1A, Ishikawa and KLE cells and 72 hours later, annexin V 
staining was assessed as a measure of cell death. Endometrial cancer cells were treated with 
either 3 nM (AN3CA, MFE296, HEC1A, Ishikawa) or 30 nM (MFE280, KLE) of paclitaxel, 
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and either 10 nM (Ishikawa), 100 nM (AN3CA, MFE296, HEC1A) or 300 nM (MFE280, 
KLE) of doxorubicin. Data is from three independent experiments and is expressed as a fold 
change over vehicle control treated cells. 
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